A Brain-Penetrating Foldamer Rescues Aβ Aggregation-Associated Alzheimer’s Disease Phenotypes in In Vivo Models
- 11 March 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the leading cause of dementia, affecting nearly 55 million people across the world. One of the central pathological factors associated with AD is the aggregation of Aβ42, a peptide product cleaved through pathological processes in AD. Under pathological conditions, Aβ42 aggregates into insoluble plaques in the brain and impairs the function of neurons, which contributes to the cognitive decline associated with AD. Therefore, the modulation of Aβ42 aggregation is considered a potential therapeutic intervention for AD. Using an Oligoquinoline-based foldamer library, we have identified a potent foldamer antagonist (SK-131) of Aβ42 aggregation. SK-131 inhibits the aggregation by inducing a α-helical structure in monomeric Aβ42. Here, we demonstrated that SK-131 rescues Aβ42 aggregation-associated phenotypes in AD cellular and multiple Caenorhabditis elegans AD models, including intracellular inhibition of Aβ42 aggregation, rescue of behavioral deficits, and attenuation of reactive oxygen species. It efficiently crosses the blood-brain barrier and demonstrates favorable pharmaceutical properties. It also potently inhibits Zn2+-mediated Aβ42 aggregation by potentially displacing Zn2+ from Aβ42. In summary, we have identified a potent brain-penetrating foldamer that efficiently rescues AD phenotypes in in vivo models. Unlike most of the therapeutic approaches that target Aβ aggregates, we have identified and validated a novel therapeutic pathway by inducing structural change in Aβ and rescuing AD phenotypes in in vivo models. This study will further aid in the quest to identify lead therapeutics to slow or stop the progression of AD.Keywords
Funding Information
- ASPIRE (AARE20-371)
- University of Denver
- National Institutes of Health (P30CA046934, S10 OD025020)
- New York University Abu Dhabi (AD389)
- Department of Chemistry and Biochemistry, The Knoebel Institute for Healthy Aging
This publication has 88 references indexed in Scilit:
- Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease TherapeuticsDrugs, 2023
- Neuropathology of Alzheimer's DiseaseNeurotherapeutics, 2022
- Generation and characterization of a tractable C. elegans model of tauopathyGeroScience, 2021
- Helical γ‐Peptide Foldamers as Dual Inhibitors of Amyloid‐β Peptide and Islet Amyloid Polypeptide Oligomerization and FibrillizationChemistry – A European Journal, 2020
- Metal binding to the amyloid-β peptides in the presence of biomembranes: potential mechanisms of cell toxicityJBIC Journal of Biological Inorganic Chemistry, 2019
- Targeting Protein-Protein Interactions for Drug Discovery2015
- Biophysical Studies of the Amyloid β‐Peptide: Interactions with Metal Ions and Small MoleculesChemBioChem, 2013
- Alzheimer's Disease: From Pathology to Therapeutic ApproachesAngewandte Chemie International Edition, 2009
- Cell Lines Derived from Hippocampal Neurons of the Normal and Trisomy 16 Mouse Fetus (a Model for Down Syndrome) Exhibit Neuronal Markers, Cholinergic Function, and Functional Neurotransmitter ReceptorsExperimental Neurology, 2002
- Preparation and characterization of an enzymatically active immobilized derivative of myosinBiochimica et Biophysica Acta (BBA) - Enzymology, 1975